Search PubMed⌕ Search

Biomedical subjects

C Fabre

Publications and source records attributed to C Fabre.

85 records · Page 5Linked to original sources
PubMedDate not supplied

Glycosylation of VIP receptors: a molecular basis for receptor heterogeneity.

Apparent molecular weights of VIP-binding proteins differ greatly according to species and to tissue. In this study, we used plasma membranes from various species (human, rat, pig) and tissues (melanoma, intestine, liver), which display major 125I-VIP-labeled components with molecular weights ranging from M(r) = 51,800 to 66,800. With the exception of porcine receptor, the various VIP receptors had similar apparent molecular weights after removal of their N-linked carbohydrates. In addition to differences in the amount of asparagine-linked glycans, our results also revealed differences in the composition of the oligosaccharide chains, which can also account for the heterogeneity in the molecular weights of the VIP receptor.

Animals↗
PubMedDate not supplied

Characterization of the oligosaccharide moiety of VIP receptor from the human pancreatic cell line BxPC-3.

The human pancreatic cell line BxPC-3 displays two classes of binding sites with high and low affinity for VIP. The order of potency of VIP-related peptides in inhibiting either [125I]VIP or [125I]N-AcPACAP27 binding and in stimulating cAMP production was typical of the human VIP receptor. By combining affinity labeling with glycosidase treatments, we have characterized the VIP receptor as a M(r) = 68,200 glycoprotein, consisting of a M(r) = 39,300 polypeptide core with at least three N-linked oligosaccharide chains. In addition, our results revealed the presence of a low amount of sialic acid residues in the carbohydrate moiety of receptor.

Adenocarcinoma↗
PubMedDate not supplied

[Current advances in the physiopathology of primary motility disorders of the esophagus].

The authors review the recent literature about the classification of primary motor disorders of the oesophagus: achalasia, diffuse oesophageal spasm, nutcracker oesophagus, hypertensive lower oesophageal sphincter and non-specific intermediary disorders. In fact these motility disorders belong to a spectrum of diseases closely related, with chronological transformation of a specific disorder to another one or to intermediary disorders. Most of the recent pathophysiological research concerned primary achalasia, secondary achalasia syndromes being a kind of experimental model. These studies point to a morphological or functional deficiency of postganglionic nerves inhibiting the lower oesophageal sphincter (LOS) through noncholinergic nonadrenergic neurotransmitters. Recent advances in the treatment of achalasia and other motility disorders are not yet based on these findings. Although calcium channel blockers, like nifedipine, lower LOS basal pressure, they are not very useful on long term relief of symptoms of achalasia. Pneumatic dilatations or cardiomyotomy still remain the best methods of treatment of this disease.

Esophageal Achalasia↗
PubMedDate not supplied

Omeprazole in the treatment of patients with severe reflux oesophagitis not responding to H2-receptor antagonists and ineligible for surgery.

In 42 patients (25 men, 17 women, mean age 62 years) with severe erosive or ulcerative oesophagitis not responding to H2-receptor antagonist treatment over at least 3 months and ineligible for surgery, omeprazole was administered at an initial dose of 40 mg/day, subsequently reduced to 20 mg after healing of the lesions. Patients had monthly clinical, endoscopic, histological and laboratory assessment over the healing period, then were reevaluated 3-monthly over one year, then 6-monthly, during the maintenance treatment. Stages of oesophagitis were based on the Savary-Miller classification, modified for stage I (erosions must be present). With 40 mg omeprazole, healing was observed in 71%, 83% and 90% of the patients after 1, 2 and 3 months of treatment, respectively. After one month of treatment, a complete healing was less frequently observed in patients with stage IV oesophagitis pre-trial (55%) than in the patients with stages I, II and III pre-trial (90%) (p less than 0.05). Ninety per cent of the patients healed at one month were asymptomatic whereas 50% of the patients with incomplete healing still had symptoms, most often dysphagia, rarely heartburn. Maintenance treatment with 20 mg was sufficient in most patients, with a probability of remaining healed of 69% from 9 to 24 months after starting this dosage. In 9 patients with Barrett's oesophagus, the lengths of the circumferential metaplasia were found to be reduced after one year of treatment compared to pre-trial lengths (p less than 0.005). There was no further significant reduction of length after 2 years of treatment. Fasting gastrin was increased in most of the patients, although great inter-patient variability was observed; 50% of the patients had levels not exceeding 5 times the upper limit of normal. There was no consistent increase of enterochromaffin-like cell density in 29 patients investigated up to nearly 2 years of omeprazole administration. The treatment was well tolerated. By inducing a profound and sustained inhibition of acid secretion, as confirmed by pH monitoring, omeprazole promotes healing of the lesions of severe oesophagitis and prevents recurrence of lesions and symptoms. Omeprazole is therefore a valuable treatment for patients ineligible for surgery, particularly in the elderly.

Adolescent↗
PubMedDate not supplied

[Multidisciplinarity in public health: the global approach and territorial dimensions].

The GRES 31 is a small study group which was established in 1982 in Toulouse, France. Its aims are to promote health among underprivileged groups such as gypsies, immigrants from North Africa... in the local communities. The local community is envisaged as an area where the social structure which has become pathogenic (bad work conditions, destruction of human links...) can be reshaped for a healthy life. The approach of GRES 31 is "global": the health problems of an individual cannot be separated from the overall life context of his group. The ethnic culture and collective behaviour of the group is closely related to the demand for care and the health outcome. On such a pre-requisite, the social scientist has to play his role together with the health professionals. The term of "research" (i.e. "social research") is to be supplemented by that of "experiment". Moreover, health promotion cannot merely imply guidance from the outside but primarily participation from inside the local communities. Such an approach is not a novelty: as a matter of fact, the works of the French hygienists in the 19th century paved the way for a pluri-disciplinary perspective in health work. In some circumstances, the "researchers-experimenters" cannot avoid certain conflicts among themselves: for example when an ill child is endangered by the observance of the ethnic traditions of his own group. More generally, efforts to reduce "clinical imperialism", "State interventionism", "local bureaucracy"... could be of light weight when dealing with "macro-problems" such as nuclear risk, AIDS, or health cost containment.

France↗